WO2012063126A3 - Improved processes for preparing pure (3ar,4s,6r,6as)-6-amino-2,2-dimethyltetrahdro-3ah-cyclopenta[d] [1,3]-dioxol-4-ol and its key starting material - Google Patents

Improved processes for preparing pure (3ar,4s,6r,6as)-6-amino-2,2-dimethyltetrahdro-3ah-cyclopenta[d] [1,3]-dioxol-4-ol and its key starting material Download PDF

Info

Publication number
WO2012063126A3
WO2012063126A3 PCT/IB2011/002889 IB2011002889W WO2012063126A3 WO 2012063126 A3 WO2012063126 A3 WO 2012063126A3 IB 2011002889 W IB2011002889 W IB 2011002889W WO 2012063126 A3 WO2012063126 A3 WO 2012063126A3
Authority
WO
WIPO (PCT)
Prior art keywords
dioxol
cyclopenta
amino
starting material
dimethyltetrahdro
Prior art date
Application number
PCT/IB2011/002889
Other languages
French (fr)
Other versions
WO2012063126A2 (en
Inventor
Arvapally Seshu Kumar
Nikhil Trivedi
Nitin Sharadchandra Pradhan
Krishnadatt Sharma
Original Assignee
Actavis Group Ptc Ehf
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Actavis Group Ptc Ehf filed Critical Actavis Group Ptc Ehf
Publication of WO2012063126A2 publication Critical patent/WO2012063126A2/en
Publication of WO2012063126A3 publication Critical patent/WO2012063126A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/02—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 2
    • C07D317/06—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 2 condensed with carbocyclic rings or ring systems

Abstract

Provided herein is an improved, commercially viable and industrially advantageous process for the preparation of a ticagrelor intermediate, (3aR,4S,6R,6aS)-6-amino-2,2- dimethyltetrahydro-3aH-cyclopenta[d][l,3]-dioxol-4-ol, which is useful for preparing ticagrelor or a pharmaceutically acceptable salt thereof in high yield and purity. The present invention further relates to an improved process for the preparation of (lS,4R)-cis-4-acetoxy- 2-cyclopenten-l-ol, which is a key starting material in the preparation of the ticagrelor intermediate.
PCT/IB2011/002889 2010-11-09 2011-10-25 Improved processes for preparing pure (3ar,4s,6r,6as)-6-amino-2,2-dimethyltetrahdro-3ah-cyclopenta[d] [1,3]-dioxol-4-ol and its key starting material WO2012063126A2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
IN3332CH2010 2010-11-09
IN3332/CHE/2010 2010-11-09
IN1594/CHE/2011 2011-05-09
IN1594CH2011 2011-05-09

Publications (2)

Publication Number Publication Date
WO2012063126A2 WO2012063126A2 (en) 2012-05-18
WO2012063126A3 true WO2012063126A3 (en) 2012-10-26

Family

ID=45478377

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2011/002889 WO2012063126A2 (en) 2010-11-09 2011-10-25 Improved processes for preparing pure (3ar,4s,6r,6as)-6-amino-2,2-dimethyltetrahdro-3ah-cyclopenta[d] [1,3]-dioxol-4-ol and its key starting material

Country Status (1)

Country Link
WO (1) WO2012063126A2 (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104211704B (en) * 2013-06-03 2017-08-25 杭州领业医药科技有限公司 Triazole [4,5 d] pyrimidine compound of crystal habit and its production and use
CN103304545B (en) * 2013-06-26 2015-05-20 苏州明锐医药科技有限公司 5-amino-1,4-disubstituent-1,2,3-triazole and preparation method thereof
CN105606741A (en) * 2016-03-10 2016-05-25 天津红日药业股份有限公司 Method for detecting content of relevant substances of Ticagrelor
CN109856255B (en) * 2017-11-30 2022-04-05 四川海思科制药有限公司 Analysis method for controlling isomer impurity content of ticagrelor intermediate
CN110412188B (en) * 2018-04-27 2022-07-26 广东东阳光药业有限公司 Method for separating and determining isomer impurities of ticagrelor intermediate
CN112098527B (en) * 2019-06-18 2022-02-25 武汉武药科技有限公司 Detection method of ticagrelor starting material
CN110627765B (en) * 2019-10-14 2021-08-20 浙江乐普药业股份有限公司 Preparation method of ticagrelor key intermediate
CN110684019B (en) * 2019-10-29 2020-08-18 株洲千金药业股份有限公司 Preparation method of ticagrelor intermediate oxide impurity
CN110642862B (en) * 2019-10-29 2021-01-26 株洲千金药业股份有限公司 Preparation method of ticagrelor ethylated impurity
CN113466371B (en) * 2021-06-30 2023-09-08 黔西县黔希煤化工投资有限责任公司 Method for determining trace diisopropyl ether in phenolic water
CN113502302A (en) * 2021-07-30 2021-10-15 江西科苑生物股份有限公司 Biosynthesis method of (S) -2-chloro-1- (3, 4-difluorophenyl) ethanol

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001036421A1 (en) * 1999-11-15 2001-05-25 Astrazeneca Ab Novel [1,2,3]-triazolo[4,5-d]pyrimidine compounds
WO2009064249A1 (en) * 2007-11-15 2009-05-22 Astrazeneca Ab A process for the preparation of (3ar,4s, 6r, 6as)-6-amino-2, 2- dimethyltetrahydro-3ah-cyclopenta[d] [1,3] dioxol-4-ol dibenzoyl-l-tartrate and to products of said process

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9702772D0 (en) 1997-07-22 1997-07-22 Astra Pharma Prod Novel compounds
AR017014A1 (en) 1997-07-22 2001-08-22 Astrazeneca Ab TRIAZOL COMPOUNDS [4,5-D] PYRIMIDINE, PHARMACEUTICAL COMPOSITIONS, USE OF THE SAME TO PREPARE MEDICATIONS AND PROCESSES FOR THE PREPARATION OF SUCH COMPOUNDS
SE9702773D0 (en) 1997-07-22 1997-07-22 Astra Pharma Prod Novel compounds
TWI229674B (en) 1998-12-04 2005-03-21 Astra Pharma Prod Novel triazolo[4,5-d]pyrimidine compounds, pharmaceutical composition containing the same, their process for preparation and uses
GB0013488D0 (en) 2000-06-02 2000-07-26 Astrazeneca Ab Chemical compound
TWI290549B (en) 2000-06-02 2007-12-01 Astrazeneca Ab Process for the preparation of cyclopropyl carboxylic acid ester and derivatives
GB0615619D0 (en) 2006-08-05 2006-09-13 Astrazeneca Ab Chemical process for preparation of intermediates
GB0615620D0 (en) 2006-08-05 2006-09-13 Astrazeneca Ab A process for the preparation of optically active intermediates
EP2326627A1 (en) 2008-08-20 2011-06-01 Schering Corporation Substituted pyridine and pyrimidine derivatives and their use in treating viral infections
DK2340252T3 (en) 2008-09-09 2016-01-18 Astrazeneca Ab PROCESS FOR THE PREPARATION OF [1S- [1 alpha, 2-ALPHA, 3 beta (1S *, 2R *), 5 beta]] - 3- [7- [2- (3,4-difluorophenyl) -CYCLOPROPYLAMINO] -5- (propylthio) -3 H -1,2,3-triazolo [4,5-d] pyrimidin-3-yl] -5- (2-hydroxyethoxy) cyclopentane-1,2-dIOL AND ITS INTERMEDIATES

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001036421A1 (en) * 1999-11-15 2001-05-25 Astrazeneca Ab Novel [1,2,3]-triazolo[4,5-d]pyrimidine compounds
WO2009064249A1 (en) * 2007-11-15 2009-05-22 Astrazeneca Ab A process for the preparation of (3ar,4s, 6r, 6as)-6-amino-2, 2- dimethyltetrahydro-3ah-cyclopenta[d] [1,3] dioxol-4-ol dibenzoyl-l-tartrate and to products of said process

Also Published As

Publication number Publication date
WO2012063126A2 (en) 2012-05-18

Similar Documents

Publication Publication Date Title
WO2012063126A3 (en) Improved processes for preparing pure (3ar,4s,6r,6as)-6-amino-2,2-dimethyltetrahdro-3ah-cyclopenta[d] [1,3]-dioxol-4-ol and its key starting material
WO2012085665A3 (en) Novel processes for preparing triazolo[4,5-d]pyrimidine derivatives and intermediates thereof
WO2009102155A3 (en) Process for preparation of 2-methyl-2´-phenylpropionic acid derivatives and novel intermediate compounds
WO2011132083A3 (en) Novel process for preparing phenylcyclopropylamine derivatives using novel intermediates
WO2008089984A3 (en) Process for the preparation of ezetimibe and derivatives thereof
WO2011048604A3 (en) Processes for the preparation of darunavir and the amorphous form thereof
WO2012001531A3 (en) Novel processes for the preparation of phenylcyclopropylamine derivatives and use thereof for preparing ticagrelor
WO2012082672A3 (en) Process and intermediates for preparing macrolactams
EP1854788B8 (en) Method for producing 1-substituted-3-fluoroalkyl pyrazole-4-carboxylate
WO2009141837A3 (en) Process for preparing posaconazole and intermediates thereof
WO2008096372A3 (en) Process for preparing highly pure ezetimibe using novel intermediates
WO2010139981A3 (en) Processes for preparing crystalline forms of dasatinib
WO2012065114A3 (en) Polyketal adducts, methods of manufacture and uses thereof
WO2010140765A2 (en) Novel method for preparing rosuvastatin, intermediate compounds useful for preparing same, and method for preparing same
WO2014006637A3 (en) Improved process for preparing benzofuran-2-carboxamide derivatives
WO2008087557A3 (en) An improved process for preparation of 9-hydroxy-3-(2-chloroethyl)- 2-methyl-4h-pyrido[1,2-a]pyrimidin-4-one hydrochloride
WO2011128784A3 (en) Novel process for preparing highly pure tapentadol or a pharmaceutically acceptable salt thereof
WO2010026603A3 (en) Novel amine salts of tenofovir, process for producing the same and use thereof in production of tenofovir dioproxil
WO2012031045A3 (en) Phosphonate ester derivatives and methods of synthesis thereof
MY155721A (en) A process for the preparation of (3ar, 4s, 6r, 6as)-6-amino-2, 2-dimethyltetrahydro-3ah-cyclopenta[d] [1,3] dioxol-4-ol dibenzoyl-l-tartrate and to products of said process
EA201300647A1 (en) OPTIMIZED SYNTHESIS OF PURE NONPOLYMORPHIC CRYSTALLINE YELLOW ACIDS WITH A PARTICLE SIZE
WO2009124906A3 (en) A polymorph of argatroban monohydrate and a process for its synthesis
WO2008099286A3 (en) Improved process for preparing ethyl (s)-2-ethoxy-4-[n-[1-(2- piperidinophenyl)-3-methyl-1-butyl]aminocarbonyl methyl]benzoate and use thereof for the preparation of repaglinide
WO2012146978A3 (en) A novel process for the preparation of tapentadol or a pharmaceutically acceptable salt thereof
WO2010119450A3 (en) An improved process for the preparation of desmopressin or its pharmaceutically acceptable salts

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11808325

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 11808325

Country of ref document: EP

Kind code of ref document: A2